Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | FADS1 | O60427 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 6/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272979 | 0.85 | HTR2C (0.38) | HTR2CTRPA1FADS1DRD1MAOA | |
| SCHEMBL18238715 | 0.73 | BRD4 (0.32) | — | |
| SCHEMBL18238843 | 0.73 | HTR2A (0.33) | HTR2CDRD1HTR2A | |
| SCHEMBL2757287 | 0.72 | HTR2C (0.47) | HTR2CTRPA1FADS1DRD1HTR2A | |
| SCHEMBL12125649 | 0.72 | ALDH1A1 (0.39) | HTR2CTRPA1FADS1DRD1HTR2A | |
| SCHEMBL22490021 | 0.72 | HTR2A (0.37) | HTR2CHTR2A | |
| SCHEMBL12395097 | 0.71 | DRD1 (0.37) | DRD1 | |
| SCHEMBL18238842 | 0.71 | HTR2A (0.36) | HTR2CHTR2A | |
| SCHEMBL26812991 | 0.71 | EGFR (0.38) | MAOA | |
| SCHEMBL8272976 | 0.69 | MAOA (0.39) | TRPA1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210047320-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10759796-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2020163193-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200123150-A1 | CXCR4 INHIBITORS AND USES THEREOF | X4 PHARMACEUTICALS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-19 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-01-11 | — | — | US | disclosed |
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2018-01-04 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2017-07-06 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759796-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | HTR2C 2383/4885TRPA1 1368/4885FADS1 4313/4885 |
| US-20210047320-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | HTR2C 2383/4885TRPA1 1368/4885FADS1 4313/4885 |
| US-20180002343-A1 | HETEROCYCLIC INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A1, SLC16A3, SLC16A7 | HTR2C 2126/4885TRPA1 1382/4885FADS1 1615/4885 |
| US-20230242531-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | HTR2C 542/4885TRPA1 1859/4885FADS1 58/4885 |
| US-20180009792-A1 | CHROMENONE INHIBITORS OF MONOCARBOXYLATE TRANSPORTERS | SLC16A3, SLC16A1, SLC16A7 | HTR2C 1677/4885TRPA1 765/4885FADS1 1594/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | HTR2C 4047/4885TRPA1 4597/4885FADS1 4599/4885 |
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | HTR2C 4284/4885TRPA1 3329/4885FADS1 354/4885 |
| US-20180008605-A1 | PTERIDINE DIONE MONOCARBOXYLATE TRANSPORTER INHIBITORS | SLC16A1, SLC16A3, SLC16A7 | HTR2C 3042/4885TRPA1 1279/4885FADS1 1649/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | HTR2C 2383/4885TRPA1 1368/4885FADS1 4313/4885 |
| US-20200123150-A1 | CXCR4 INHIBITORS AND USES THEREOF | CXCR4, CXCL12, CXCR3 | HTR2C 2383/4885TRPA1 1368/4885FADS1 4313/4885 |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | PHGDH, PGD, PGK1 | HTR2C 4178/4885TRPA1 3251/4885FADS1 388/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | HTR2C 4047/4885TRPA1 4597/4885FADS1 4599/4885 |
| US-11306088-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | HTR2C 2383/4885TRPA1 1368/4885FADS1 4313/4885 |
| US-20170190715-A1 | PYRIDINE DERIVATIVE | LAP3, PREP, DNPEP | HTR2C 1434/4885TRPA1 1244/4885FADS1 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.